NEFL and myeloid sarcoma: Its potential neuroprotective effect is supported by the observed reduction in neurofilament light chain levels in MS patients receiving cladribine tablets treatment [40] and by the capacity of oral cladribine treatment to normalize the hyperactivity of the cortical neuronal network induced in the EAE mouse model [41].